The board of directors biopharmaceutical company Merck (NYSE:MRK) declared a dividend of USD0.61 per share on the company's common stock for the second quarter of 2020, it disclosed on Tuesday.
This dividend is payable on 7 July 2020 to shareholders of record at the close of business as of 15 June 2020.
Merck said it continues to be at the forefront of research to prevent and treat diseases that threaten people and animals, including cancer, infectious diseases, HIV and Ebola, as well as emerging animal diseases.
Bruker demonstrates advancements in 4D-Proteomics at US HUPO
Mitem Pharma acquires Flisint rights from Sanofi to address rare infectious disease
Audientes partners with Audivista to expand hearing solutions in Middle East and North Africa
Benuvia Operations signs licensing deal with Avernus Pharma
Benuvia Operations signs licensing and supply agreements with Medra Brasil Medicamentos
Castle Biosciences to present data on Melanoma tests at ASDP Annual Meeting
Alchemy partners with PatchRx to improve HIV medication adherence
Gilead expands global access to lenacapavir for HIV prevention